Usefulness of ADCratio (rADC) for prostate cancer aggressiveness assessment in patient treated with 5-alpha-reductase inhibitors (5-ARI) for benign prostate hypertrophy (BPH)

Poster: "ECR 2018 / C-1115 / Usefulness of ADCratio (rADC) for prostate cancer aggressiveness assessment in patient treated with 5-alpha-reductase inhibitors (5-ARI) for benign prostate hypertrophy (BPH)" by: "L. Basso, S. Migone, C. bergaglio, F. Rosa, V. Prono, L. Secondini, I. Verardo, G. Perugin, C. E. Neumaier; Genoa/IT"